How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across ...

Investors in Halozyme Therapeutics, Inc. HALO need to pay close attention to the stock based on moves in the options market lately. That is because the March 21, 2025 $25.00 Call had some of the ...

TD Cowen analyst Brendan Smith reiterated a Buy rating on Halozyme (HALO – Research Report) today and set a price target of $77.00.Stay Ahead ...

Leerink Partners analyst David Risinger maintained a Hold rating on Halozyme (HALO – Research Report) on January 12 and set a price target of ...

Halozyme Therapeutics, Inc.'s subcu drug delivery business, driven by ENHANZE technology, shows strong revenue growth with significant collaborations, but faces potential challenges post-2030 due ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $64.55, a high estimate of $73.00, and a low estimate of $52.00. Marking an increase of 0.44%, the current ...

SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full year 2024 financial guidance ...

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...